IceCure CFO to Exit After Nine Years Following Nasdaq Listing and FDA Clearance
Chief Financial Officer Ronen Tsimerman will depart IceCure after nine years, having overseen its Nasdaq listing and key fundraisings supporting the ICE3 study. His tenure also saw FDA clearance of ProSense® for low-risk breast cancer, and the company has initiated a search with several candidates advancing to board interviews.
1. CFO Departure Announcement
IceCure has announced that CFO Ronen Tsimerman will step down after nearly nine years, effective upon appointment of a successor. He will remain in his role through the transition period to ensure continuity of financial leadership.
2. Key Milestones Under Tsimerman
During his tenure, Tsimerman led IceCure’s Nasdaq listing, secured multiple fundraising rounds to complete the ICE3 cryoablation study, and achieved FDA marketing clearance for the ProSense® system for low-risk breast cancer in late 2025.
3. Succession Planning
The company has initiated a search for a new CFO, citing candidates with extensive experience commercializing disruptive technologies. Several applicants have advanced to interviews with the Board of Directors to fill the vacancy.